After years of manufacturing woes torpedoed their chances to challenge Sanofi's blockbuster insulin injection Lantus, Mylan and Biocon recently received the FDA's go-ahead to launch their knockoff.

The product site for Sanofi-Aventis’s insulin injection Lantus received the highest mark in terms of consumer satisfaction, according to a Manhattan Research study. The website (which features ...

GoodRx, a resource for healthcare savings and information, is working with Sanofi, a company that specializes in diabetes care, to offer people living with diabetes access to Lantus (insulin glargine ...

PARIS, France, June 9, 2012-- Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c - glycated hemoglobin ...

Share on Pinterest Semglee is an alternative for people with diabetes who now use long-acting injectable insulin products such as Lantus. Getty Images The Food and Drug Administration (FDA) has ...

Sanofi will cut insulin prices by 70% or more and cap out-of-pocket costs at $35 for people with commercial insurance Sanofi follows Eli Lilly and Novo Nordisk in announcing insulin price cuts.

Sanofi announced full results from EDITION II (basal insulin + oral therapy) and additional results from its EDITION Phase 3 program for EDITION III, EDITION IV, and EDITION JP I for the ...

(Reuters) - U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi's infringement claims relating to insulin drug Lantus. Sanofi is ...

The product site for Sanofi-Aventis’s insulin injection Lantus received the highest mark in terms of consumer satisfaction, according to a Manhattan Research study. The site (which features optional ...